UNSPSC 51271701: Phenacaine

This classification denotes an anesthetic agent with the molecular formula C18H22N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V3M4D317W8, chemically known as n,n(sup 2)-bis(p-ethoxyphenyl)acetamidine but generally known as phenacaine, which bears US NIH Compound Identifier 7588. European Medicines Agency schedules Phenacaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09743MIG. The term PHENACAINE is an International Non-Proprietary Name.

UNSPSC 51271701 Phenacaine, a Commodity code, encompasses pharmaceutical ingredients and finished-form products that state and local health systems, correctional facilities, and public health agencies procure through cooperative purchasing vehicles and direct solicitation. State and local governments buy phenacaine and similar local anesthetic compounds primarily as components in ophthalmologic and topical preparations used across public health clinics, hospitals, and emergency departments. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, serves as a significant aggregation vehicle for this category, drawing participation from multiple states including Oregon and licensing purchases across authorized pharmaceutical wholesalers — AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC. Issuing bodies soliciting under this code range from state health and human services departments to county hospital systems and public university medical centers; cooperative purchasing alliances like MMCAP consolidate demand across dozens of participating jurisdictions and reduce transaction costs for smaller public agencies.

MMCAP posted a Request for Proposal on January 20, 2026 (S1070000015802) to establish multiple contracts for generic pharmaceuticals and OTC products, with a March 26, 2026 response deadline. The solicitation required vendors to provide comprehensive product information including National Drug Codes, SKUs, and UPCs, with pricing weighted at 75 percent of the evaluation and administrative compliance and EDI capability each at 5 percent. Awards became effective July 1, 2026, with a two-year initial term and optional extensions; vendors must maintain $5 million commercial general liability coverage, certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, and accept a 3 percent administrative fee on all purchases. The solicitation does not identify specific set-aside designations. The source supports no additional recent state or local opportunities under this Commodity code beyond the MMCAP solicitation.